Dissecting the biological relevance and clinical impact of lncrna miat in multiple myeloma

Katia Todoerti, Domenica Ronchetti, Noemi Puccio, Ilaria Silvestris, Vanessa Favasuli, Nicola Amodio, Massimo Gentile, Fortunato Morabito, Antonino Neri, Elisa Taiana

Research output: Contribution to journalArticlepeer-review


The biological impact of long non-coding RNAs (lncRNAs) in multiple myeloma (MM) is becoming an essential aspect of the investigation, which may contribute to understanding the dis-ease’s complex pathobiology, providing novel potential therapeutic targets. Herein, we investigated the expression pattern and the clinical relevance of the lncRNA MIAT in MM, taking advantage of the publicly available CoMMpass database. MIAT expression in MM is highly heterogeneous and significantly associated with specific molecular lesions frequently occurring in MM. Transcriptome analyses of MM PCs from patients included in the CoMMpass database indicated a potential involvement of MIAT in different signaling pathways and ribosome biogenesis and assembly. These findings suggest that MIAT deregulation may play a pathogenetic role in MM by affecting both proliferation pathways and, indirectly, the translational process. Although MIAT expression levels seem not to be significantly associated with clinical outcome in multivariate analyses, high MIAT expression levels are associated with bortezomib resistance, this suggesting that MIAT targeting could overcome drug resistance in MM. These findings strongly prompt for further studies investigating the significance of MIAT in MM.

Original languageEnglish
Article number5518
Issue number21
Publication statusPublished - Nov 1 2021


  • Bortezomib
  • MIAT
  • Multiple myeloma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Dissecting the biological relevance and clinical impact of lncrna miat in multiple myeloma'. Together they form a unique fingerprint.

Cite this